Allergan (NYSE: AGN) is expected to report Q2 earnings around July 30. Here's what Wall Street wants to see:

The 10-second takeaway
 Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Allergan's revenues will increase 4.9% and EPS will increase 12.1%.

The average estimate for revenue is $1.56 billion. On the bottom line, the average EPS estimate is $1.20.

Revenue details
 Last quarter, Allergan reported revenue of $1.46 billion. GAAP reported sales were 8.3% higher than the prior-year quarter's $1.35 billion.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 Last quarter, non-GAAP EPS came in at $0.98. GAAP EPS of $0.04 for Q1 were 95% lower than the prior-year quarter's $0.75 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
 For the preceding quarter, gross margin was 86.9%, 100 basis points better than the prior-year quarter. Operating margin was 27.5%, 60 basis points better than the prior-year quarter. Net margin was 0.9%, much worse than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $6.16 billion. The average EPS estimate is $4.74.

Investor sentiment
 The stock has a four-star rating (out of five) at Motley Fool CAPS, with 419 members out of 444 rating the stock outperform, and 25 members rating it underperform. Among 118 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 115 give Allergan a green thumbs-up, and three give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Allergan is outperform, with an average price target of $114.06.